• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Macrolide Antibiotics During Pregnancy: Is There a Link to Congenital Malformations?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Macrolide antibiotics include erythromycin, clarithromycin, and azithromycin
  • Studies have provided conflicting results
  • Andersson et al. (BMJ, 2021) assessed the association between the use of macrolide antibiotics in pregnancy and the risk of major birth defects

METHODS:

  • Nationwide, register based cohort study (1997 to 2016)
  • Participants
    • Pregnancies ending with live birth
  • Exposures
    • Macrolide use during first trimester (start of pregnancy through 12 weeks), compared with
      • Penicillin use during pregnancy | Matched 1:1
      • Recent macrolide use (six months to one month before becoming pregnant) | Matched 1:1
      • No antibiotics (from one month before or in the first trimester of pregnancy): Matched 1:4
  • Primary outcome
    • Any major birth defect
    • Subgroups of birth defects

RESULTS:

  • 1,192,539 live birth pregnancies
    • Macrolide use during pregnancy: 13,019 pregnancies
  • Infants born with major birth defects
    • Macrolide use during pregnancy: 35.1 per 1000 pregnancies
    • Penicillin use during pregnancy: 37.0 per 1000 pregnancies
    • RR 0.95 (95% CI, 0.84 to 1.08)
    • Absolute risk difference −1.8 per 1000 pregnancies (95% CI, −6.4 to 2.7)
  • Similar to penicillin use, there was no increased risk when comparing macrolide use during pregnancy vs
    • Recent macrolide use but not during pregnancy
      • RR 1.00 (95% CI, 0.88 to 1.14)
      • Absolute risk difference −0.1 per 100 pregnancies (95% CI, −4.8 to 4.7)
    • No antibiotic use
      • RR 1.05 (95% CI, 0.95 to 1.17)
      • Absolute risk difference 1.8 per 1000 pregnancies (95% CI, −1.7 to 5.3)
  • Birth defect subgroup analysis
    • No increased risk with macrolide use in pregnancy was identified for specific birth defects
  • No differences were found when analyses were performed for the individual macrolides
  • Second and third trimester exposures (post hoc analyses)
    • No association with increased risk for major birth defects
    • RR 1.02 (95% CI, 0.93 to 1.12)

CONCLUSION:

  • In this Danish cohort, there was no association between macrolide use during pregnancy and increased risk of congenital birth defects 
  • The authors conclude

In contrast with a recent cohort study from the UK, we found no significantly increased risk of any of the 12 organ specific subgroups of birth defects, including defects of the heart, and no evidence of significant associations for individual macrolides

Learn More – Primary Sources:

Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Is Macrolide Antibiotic Use During Pregnancy Linked to Increased Risk of Congenital Malformations?
Does Antibiotic Use Increase Risk of Spontaneous Abortion?
Do Common Antibiotics Increase Risk of Congenital Malformations?
Is Antibiotic Exposure in Pregnancy or Childhood Linked with Childhood Obesity?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site